Clinical trials: SAR
Allergic Rhinitis
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
- Trial name
- NCT00728416
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 333 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis, Sinusitis
A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.
The purpose of this study is to establish whether MRI scanning is a sensitive measure of the effects of existing drug treatments on nasal dimensions following challenge with intranasal allergen in subjects with hayfever.
- Trial name
- NCT00517946
- Testing
- pseudoephedrine hydrochloride, cetirizine hydrochloride
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Seasonal
Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)
The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
- Trial name
- NCT00807053
- Testing
- Ciclesonide HFA
- Where
- 31 sites in United States
- Volunteers
- 480 people
- Sponsor
- AstraZeneca
Hay Fever, Seasonal Allergic Rhinitis
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily.
- Trial name
- NCT00305487
- Testing
- Ciclesonide nasal spray
- Where
- 71 sites in United States
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis
Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)
This is study of LMC, phenylephrine, and placebo in subjects with SAR. There are three visits: At Visit 1, subjects will be evaluated for participation and, if they qualify, will attend Visit 2 for priming.
- Trial name
- NCT00423995
- Testing
- Loratadine/montelukast combination
- Volunteers
- 379 people
- Sponsor
- Organon and Co
Rhinitis, Allergic, Seasonal
The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)
This is a Phase 3, single-dose, investigator-blind, randomized, placebo-controlled, crossover study, conducted at a single site in Austria, outside of the normal grass pollen season.
- Trial name
- NCT00276016
- Testing
- phenylephrine, pseudoephedrine
- Volunteers
- 39 people
- Sponsor
- Organon and Co
Prostatic Neoplasms, Castration-Resistant
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Trial name
- SECuRE (NCT04868604)
- Testing
- 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Allergic Rhinitis
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
- Trial name
- NCT00733005
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 324 people
- Sponsor
- Organon and Co
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00430157
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis, Seasonal Allergic Conjunctivitis
Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents
Ectoin acts on membranes by forming an Ectoin-Hydro-Complex therewith providing a protection against external agents like aeroallergens.
- Trial name
- NCT01342601
- Testing
- ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)
- Where
- 8 sites in Germany
- Volunteers
- 72 people
- Sponsor
- Bitop AG
Seasonal Allergic Rhinitis
New Nasal Applicator / New Formulation - User Study
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).
- Trial name
- NCT00641979
- Testing
- budesonide
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)
This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period.
- Trial name
- NCT00783146
- Testing
- desloratadine, fexofenadine
- Volunteers
- 728 people
- Sponsor
- Organon and Co
SAR
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas
This clinical study is to investigate the safety and tolerability of CCT301-38 CAR modified autologous T cells (CCT301-38) in subjects with relapsed or refractory AXL positive sarcomas
- Trial name
- NCT05128786
- Testing
- CCT301-38
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Seasonal Allergic Rhinitis, Hayfever
Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR
This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.
- Trial name
- NCT00854360
- Testing
- Beclomethasone dipropionate HFA Nasal Aerosol
- Where
- 26 sites in United States
- Volunteers
- 487 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hay Fever
Safety and Efficacy Study of rEV131 in Allergic Rhinitis
The purpose of this study is to see whether rEV131 when given as a nasal spray in a single dose to each nostril is safe and can reduce the signs and symptoms of allergic rhinitis (hay fever) caused by an allergen challenge.
- Trial name
- NCT00247520
- Testing
- topical nasal rEV131
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Evolutec Group
Seasonal Allergic Rhinitis
To Study GSP 301 in Patients With Seasonal Allergic Rhinitis
Study to evaluate the two different strengths and dose regimen of GSP 301 to be effective in treatment of seasonal allergic rhinitis.
- Trial name
- NCT02318303
- Testing
- GSP 301-1 NS (QD), GSP 301-2 NS (BID), Olopatadine HCl-1 NS (QD)
- Where
- 10 sites in United States
- Volunteers
- 1,111 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Choroidal Melanoma, Indeterminate Lesions
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
This is a prospective multicenter, group-matched study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with belzupacap sarotalocan (bel-sar; AU-011) and patients who are planned to…
- Trial name
- IL (NCT05266430)
- Testing
- Standard of Care, AU-011
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Aura Biosciences
Rhinitis, Allergic, Seasonal
A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
This current study is planned as a dedicated pharmacodynamic (effect of drug on the body) study to investigate the dose response in rhinitic subjects at doses where GSK256066 has been proven to work (200mcg) or expected to…
- Trial name
- NCT00464568
- Testing
- GSK256066
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic, Seasonal
Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen
To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg, administered once daily during two consecutive days, on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an…
- Trial name
- NCT00315523
- Testing
- Levocetirizine
- Where
- Canada
- Volunteers
- 403 people
- Sponsor
- UCB Pharma
Seasonal Allergic Rhinitis
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)
This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period.
- Trial name
- NCT00783211
- Testing
- desloratadine, fexofenadine
- Volunteers
- 722 people
- Sponsor
- Organon and Co